2022 Fiscal Year Final Research Report
Establishment of a method for predicting the onset of preeclampsia and verification of the preventive effect of low-dose aspirin
Project/Area Number |
19K18653
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
Research Institution | Showa University |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Keywords | 妊娠高血圧腎症 / アスピリン / 発症予測 |
Outline of Final Research Achievements |
It was investigated that the usefulness of a method for extracting pregnant women at high risk of developing preeclampsia (PE) in early pregnancy in Japanese population. The combination of maternal background, mean blood pressure, bilateral uterine artery PI, and PlGF at 11-13 weeks of gestation resulted in a screening positive rate of 10% and a detection rate of 91% for preterm PE, compared with Europeans. The result was published as "Accuracy of the FMF Bayes theorem-based model for predicting preeclampsia at 11-13 weeks of gestation in a Japanese population" in Hypertension Research. In addition, for the prediction of PE onset, it was shown that screening at two stages of pregnancy, at 11-13 weeks and at 19-24 weeks of gestation using maternal blood pressure and serum PlGF level/serum sFlt-1/PlGF ratio may be useful in Japanese population. Furthermore, low-dose aspirin intake was shown not to affect PE risk assessment biomarkers at 11-13 weeks of gestation.
|
Free Research Field |
周産期
|
Academic Significance and Societal Importance of the Research Achievements |
妊娠初期に妊娠高血圧腎症発症ハイリスク妊婦を抽出し低用量アスピリンを投与することにより発症予防することの研究成果が欧州の多施設共同研究で示されたが日本人では十分検討されていない。そこでスクリーニング法とアスピリンによる予防効果をアジア人で確認する国際的共同研究を立ち上げた。この研究において妊娠11-13週に採血した検体を用い、ハイリスク妊婦を抽出するためのより感度の良いバイオマーカーの抽出を行った。妊娠初期のデータに妊娠中期の血清マーカーを組み合わせることで、より精度高く予測できることが示された。また、妊娠高血圧腎症発症予知スクリーニング実施時点でのアスピリン内服の影響がないことも確認できた。
|